Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02908672
Title	A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Hoffmann-La Roche
Indications	melanoma
Therapies	Cobimetinib + Vemurafenib Atezolizumab + Cobimetinib + Vemurafenib
Age Groups:	adult \| senior
Covered Countries	USA \| NZL \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUT \| AUS